Nitsan Halevy
Direttore Tecnico/Scientifico/R&S presso PLURI INC.
Posizioni attive di Nitsan Halevy
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| PLURI INC. | Direttore Tecnico/Scientifico/R&S | 01/03/2021 | - |
Storia della carriera di Nitsan Halevy
Precedenti posizioni note di Nitsan Halevy
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | - | - |
Formazione di Nitsan Halevy
| Ben-Gurion University of the Negev | Doctorate Degree |
Statistiche
Distribuzione geografica
| Israele | 3 |
| Stati Uniti | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PLURI INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Borsa valori
- Insiders
- Nitsan Halevy
- Esperienza
